Named on one round in the feed.
Since 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Nova Anchora A biotechnology company developing a corrective topical protein therapy for dystrophic epidermolysis bullosa (DEB) | Funding round Verified against 4 of 8 sources | $23M | 2026-11-05 | [ PART ] |